Revenue is what people want to see. Current market cap is approx $9.8m and Epichem is expected to make $4m this FY. The deal with Elanco removes a lot of the financial burden of running the clinical trials so the cash position of the company is enough to sustain current operations.
I can't explain why people are selling but I know why I am buying.
PAA
Price at posting:
4.9¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.